戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 sruptions, and consolidations in the generic-drug industry.
2 ng-standing and expensive antitarget for the drug industry.
3  criticized as a "windfall" to the innovator drug industry.
4 mercial application of fungi in the food and drug industries.
5 should to be of interest to neuroscientists, drug industry and the general public alike.
6  and the role of protein therapeutics in the drug industry continue to expand, alternative strategies
7 past-will ultimately prove invaluable to the drug industry in the ongoing battle against infectious d
8                  Reduced productivity in the drug industry is caused mainly by corporate policies tha
9 l as tighter quality control in the Food and Drug Industry is paramount to reducing nephrolithiasis r
10 vatives is a prominent issue in the food and drug industries, reflecting demand for natural alternati
11 lication of GBPs in the food, cosmetics, and drugs industries such as micelles, liposomes, and nano-e
12 ruly entice investment and research from the drug industry, the bill needs to simplify the path to re
13                  Financial payments from the drug industry to U.S. physicians are common.
14 he application of bioactives in the food and drug industry with low toxicity.